Disease · MONDO_0003210

intrahepatic cholangiocarcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. intrahepatic cholangiocarcinoma. Diseases, record MONDO_0003210. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0003210

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: intrahepatic cholangiocarcinoma; Open Targets
Open Targets ID: MONDO_0003210; Open Targets
Other names: ICC, cholangiocarcinoma, intrahepatic, malignant, intrahepatic Cholangiocellular carcinoma, intrahepatic bile duct cancer (cholangiocarcinoma), intrahepatic bile duct carcinoma, intrahepatic carcinoma of bile duct, intrahepatic carcinoma of the bile duct, intrahepatic cholangiocarcinoma (bile duct cancer), peripheral cholangiocarcinoma; Open Targets
Disease Ontology: DOID:4928; Disease Ontology
NCI Thesaurus: C35417; NCI Thesaurus
Highest stage of its drugs: Approval, for 1 of its 84 drugs, from TTD; Open Targets

Drugs84

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
FUTIBATINIB	CHEMBL3701238	Small molecule	Approval	TTD	2	1	1	Drugs and targets
GEMCITABINE	CHEMBL888	Small molecule	Phase 3	ClinicalTrials.gov	74	74	74	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	43	43	43	Drugs and targets
OXALIPLATIN	CHEMBL414804	Small molecule	Phase 3	ClinicalTrials.gov	35	35	33	Drugs and targets
LENVATINIB	CHEMBL1289601	Small molecule	Phase 3	ClinicalTrials.gov	30	30	30	Drugs and targets
FLUOROURACIL	CHEMBL185	Small molecule	Phase 3	ClinicalTrials.gov	16	16	14	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 3	ClinicalTrials.gov	14	14	10	Drugs and targets
TORIPALIMAB	CHEMBL4297843	Antibody	Phase 3	ClinicalTrials.gov	12	12	12	Drugs and targets
IRINOTECAN	CHEMBL481	Small molecule	Phase 3	ClinicalTrials.gov	10	10	8	Drugs and targets
LEUCOVORIN	CHEMBL1679	Small molecule	Phase 3	ClinicalTrials.gov	8	8	7	Drugs and targets

1 to 10 of 84

See all 84 drugs

Targets206

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDCD1	Programmed cell death protein 1	10	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 3	https://conductscience.org/library/genes/5133	Drugs and targets
KDR	Vascular endothelial growth factor receptor	9	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3791	Drugs and targets
FGFR1	Fibroblast growth factor receptor	7	Fibroblast growth factor receptor 1 inhibitor; Fibroblast growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/2260	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	7	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2324	Drugs and targets
CD274	Programmed cell death 1 ligand 1	6	Programmed cell death 1 ligand 1 binding agent; Programmed cell death 1 ligand 1 inhibitor	Phase 2	https://conductscience.org/library/genes/29126	Drugs and targets
FGFR2	Fibroblast growth factor receptor	6	Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/2263	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	6	Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2321	Drugs and targets
FGFR3	Fibroblast growth factor receptor	5	Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/2261	Drugs and targets
TYMS	Thymidylate synthase	5	Thymidylate synthase inhibitor	Phase 3	https://conductscience.org/library/genes/7298	Drugs and targets
FGFR4	Fibroblast growth factor receptor	4	Fibroblast growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/2264	Drugs and targets

1 to 10 of 206

See all 206 targets

Trials157

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04163900	Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer	Phase 3	773	2023-05-24	Biliary Tract Cancer	CISPLATIN, FOSGEMCITABINE PALABENAMIDE, GEMCITABINE	Its record names the disease	ClinicalTrials.gov
NCT03768414	Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers	Phase 3	452	2024-10-22	Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Distal Bile Duct Cancer AJCC v8, Stage IIIA Gallbladder Cancer AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Distal Bile Duct Cancer AJCC v8, Stage IIIB Gallbladder Cancer AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Stage IVA Gallbladder Cancer AJCC v8, Stage IVB Gallbladder Cancer AJCC v8, Unresectable Extrahepatic Bile Duct Carcinoma, Unresectable Gallbladder Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma	CISPLATIN, GEMCITABINE HYDROCHLORIDE, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT02052778	A Study of TAS-120 in Patients With Advanced Solid Tumors	Phase 1/2	407	2024-03-20	Cholangiocarcinoma, Urothelial Cancer, Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors, Primary CNS Tumors, Breast Cancer, Gastric Cancer	FUTIBATINIB	Its record names the disease	ClinicalTrials.gov
NCT00753675	Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer	Phase 2	174	2013-11-28	Biliary Tract Cancer, Gallbladder Cancer, Cancer Of The Extrahepatic Bile Duct, Ampullary Carcinoma	GEMCITABINE, VANDETANIB	Its record names the disease	ClinicalTrials.gov
NCT03230318	Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma	Phase 2	148	2023-12-19	Intrahepatic Cholangiocarcinoma, Combined Hepatocellular and Cholangiocarcinoma	DERAZANTINIB	Its record names the disease	ClinicalTrials.gov
NCT01752920	Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations	Phase 1/2	119	2021-10-28	Solid Tumor	DERAZANTINIB	Its record names the disease	ClinicalTrials.gov
NCT03684811	A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation	Phase 1/2	93	2023-01-25	Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme), Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas), Cohort 3a and 3b: Chondrosarcoma, Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma, Cohort 5a: Other Non-Central Nervous System Solid Tumors With IDH1 Mutations	AZACITIDINE, CISPLATIN, GEMCITABINE, NIVOLUMAB, OLUTASIDENIB	Its record names the disease	ClinicalTrials.gov
NCT02807181	SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma	Phase 2/3	89	2025-05-09	Intrahepatic Cholangiocarcinoma	CISPLATIN, GEMCITABINE	Its record names the disease	ClinicalTrials.gov
NCT04212221	MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients	Phase 1/2	89	2024-07-23	Advanced Hepatocellular Carcinoma (HCC)	BRIVANIB ALANINATE, TEBOTELIMAB	Its record names the disease	ClinicalTrials.gov
NCT03267940	Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma	Phase 1	85	2020-02-07	Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Intrahepatic, Cholangiocarcinoma, Extrahepatic, Gallbladder Adenocarcinoma	ATEZOLIZUMAB, CISPLATIN, GEMCITABINE, PEGVORHYALURONIDASE ALFA	Its record names the disease	ClinicalTrials.gov

1 to 10 of 157

See all 157 trials

Comparisons in its trials34

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
A - NUC-1031 and Cisplatin vs B - Gemcitabine and Cisplatin: deaths from any cause	188 of 388	135 of 385	773	NCT04163900	Trial comparisons
A - NUC-1031 and Cisplatin vs B - Gemcitabine and Cisplatin: serious adverse events	175 of 383	126 of 378	761	NCT04163900	Trial comparisons
A - NUC-1031 and Cisplatin vs B - Gemcitabine and Cisplatin: Objective Response Rate (ORR)	53 of 284	34 of 275	559	NCT04163900	Trial comparisons
Gem+Cisplatin+Nab-paclitaxel vs Gemcitabine + Cisplatin: deaths from any cause	237 of 294	115 of 147	441	NCT03768414	Trial comparisons
Gem+Cisplatin+Nab-paclitaxel vs Gemcitabine + Cisplatin: serious adverse events	27 of 287	11 of 134	421	NCT03768414	Trial comparisons
Substudy 1 vs Substudy 2: deaths from any cause	74 of 103	25 of 44	147	NCT03230318	Trial comparisons
Substudy 1 vs Substudy 2: serious adverse events	37 of 103	16 of 44	147	NCT03230318	Trial comparisons
Chemotherapy (Cisplatin-Gemcitabine) vs Radiation: SIRT + Chemotherapy (Cisplatin-Gemcitabine): deaths from any cause	28 of 48	24 of 41	89	NCT02807181	Trial comparisons
Chemotherapy (Cisplatin-Gemcitabine) vs Radiation: SIRT + Chemotherapy (Cisplatin-Gemcitabine): serious adverse events	17 of 48	21 of 41	89	NCT02807181	Trial comparisons
High Dose vs Low Dose: deaths from any cause	1 of 32	0 of 28	60	NCT02392637	Trial comparisons

1 to 10 of 34

See all 34 comparisons in its trials

Papers from its trials85

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
33890170	RESULT	1	PubMed
33200010	RESULT	1	PubMed
32372672	RESULT	1	PubMed
31670746	RESULT	1	PubMed
31255499	RESULT	1	PubMed
31239717	RESULT	1	PubMed
30998813	RESULT	2	PubMed
30785198	RESULT	1	PubMed
30420614	RESULT	2	PubMed
29875066	RESULT	1	PubMed

1 to 10 of 85

See all 85 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0003210

GET https://conductscience.org/api/diseases/v1/MONDO_0003210/drugs?page=2

API reference For AI assistants